Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
| Previous Close | 1.960 |
| Open | 1.960 |
| Bid | 1.860 x N/A |
| Ask | 1.880 x N/A |
| Day's Range | 1.850 - 2.000 |
| 52 Week Range | 1.380 - 7.770 |
| Volume | |
| Avg. Volume | 2,097,665 |
| Market Cap | 1.473B |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.500 |
| Earnings Date | Mar 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.45 |
PR NewswireJacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.
PR NewswireJacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024.
PR NewswireJacobio Pharma Announces 2023 Annual Results
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was RMB 1.2 billion. Jacobio Pharma also announced its recent business progress and expected milestones.
